Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 9 | 2023 | 144 | 2.530 |
Why?
|
| Lung Neoplasms | 15 | 2024 | 553 | 1.910 |
Why?
|
| Antineoplastic Agents | 8 | 2016 | 190 | 1.810 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 14 | 2024 | 244 | 1.640 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2022 | 54 | 0.900 |
Why?
|
| Molecular Targeted Therapy | 3 | 2013 | 35 | 0.870 |
Why?
|
| Metastasectomy | 1 | 2021 | 7 | 0.770 |
Why?
|
| Antibodies, Monoclonal | 4 | 2016 | 199 | 0.730 |
Why?
|
| Bone Neoplasms | 3 | 2022 | 120 | 0.730 |
Why?
|
| Immunotherapy | 3 | 2021 | 56 | 0.690 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2019 | 241 | 0.640 |
Why?
|
| Direct-to-Consumer Advertising | 1 | 2016 | 1 | 0.530 |
Why?
|
| Medical Oncology | 1 | 2016 | 42 | 0.510 |
Why?
|
| Chemoradiotherapy | 4 | 2019 | 61 | 0.490 |
Why?
|
| Retrospective Studies | 16 | 2023 | 3612 | 0.450 |
Why?
|
| Prognosis | 9 | 2023 | 825 | 0.440 |
Why?
|
| ErbB Receptors | 4 | 2018 | 54 | 0.430 |
Why?
|
| Melanoma | 1 | 2013 | 60 | 0.400 |
Why?
|
| Neoplasm Staging | 11 | 2024 | 371 | 0.360 |
Why?
|
| Humans | 28 | 2024 | 28436 | 0.340 |
Why?
|
| Survival Rate | 5 | 2021 | 356 | 0.290 |
Why?
|
| Mutation | 3 | 2021 | 353 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2018 | 177 | 0.260 |
Why?
|
| Neutrophils | 2 | 2023 | 110 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 63 | 0.220 |
Why?
|
| Body Composition | 1 | 2024 | 69 | 0.220 |
Why?
|
| Female | 17 | 2024 | 15730 | 0.220 |
Why?
|
| Male | 16 | 2024 | 15291 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 206 | 0.220 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2013 | 19 | 0.210 |
Why?
|
| Middle Aged | 12 | 2024 | 9269 | 0.210 |
Why?
|
| Quinazolines | 2 | 2012 | 16 | 0.200 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 47 | 0.190 |
Why?
|
| Pneumonectomy | 1 | 2021 | 77 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 17 | 0.180 |
Why?
|
| Lung | 1 | 2021 | 170 | 0.180 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 147 | 0.180 |
Why?
|
| Autoantibodies | 1 | 2021 | 80 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2021 | 3615 | 0.160 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 202 | 0.160 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 11 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 68 | 0.140 |
Why?
|
| Aged | 11 | 2024 | 9277 | 0.140 |
Why?
|
| Survival Analysis | 5 | 2021 | 267 | 0.140 |
Why?
|
| Palliative Care | 2 | 2015 | 109 | 0.140 |
Why?
|
| Adult | 7 | 2022 | 8107 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 50 | 0.120 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 102 | 0.120 |
Why?
|
| Gene Dosage | 2 | 2012 | 18 | 0.120 |
Why?
|
| Biomarkers | 1 | 2018 | 596 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 1 | 2014 | 21 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 7 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 15 | 0.110 |
Why?
|
| Neoplasms | 1 | 2016 | 239 | 0.110 |
Why?
|
| Forecasting | 1 | 2013 | 103 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 1859 | 0.100 |
Why?
|
| Weight Gain | 1 | 2012 | 66 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 7 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 37 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 34 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 42 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2013 | 688 | 0.090 |
Why?
|
| Adolescent | 2 | 2016 | 2307 | 0.090 |
Why?
|
| Young Adult | 2 | 2016 | 2069 | 0.090 |
Why?
|
| Body Weight | 2 | 2024 | 144 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2010 | 20 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2010 | 22 | 0.090 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2010 | 6 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 14 | 0.090 |
Why?
|
| Lymphocytes | 2 | 2023 | 63 | 0.090 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 30 | 0.090 |
Why?
|
| United States | 1 | 2016 | 2201 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 112 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 80 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 239 | 0.080 |
Why?
|
| Child | 1 | 2013 | 1420 | 0.080 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 9 | 0.080 |
Why?
|
| Animals | 2 | 2013 | 3780 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 9 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2007 | 50 | 0.070 |
Why?
|
| Carcinoma, Large Cell | 2 | 2018 | 12 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1809 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 66 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 179 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 4857 | 0.060 |
Why?
|
| Etoposide | 2 | 2015 | 26 | 0.060 |
Why?
|
| Carboplatin | 2 | 2015 | 24 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2015 | 44 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 16 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 16 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 409 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2022 | 31 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2024 | 465 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 35 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 53 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 89 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 9 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 39 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 17 | 0.050 |
Why?
|
| Observer Variation | 1 | 2021 | 102 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2015 | 1926 | 0.040 |
Why?
|
| Patient Selection | 1 | 2021 | 206 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 13 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 11 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 52 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 54 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 84 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 730 | 0.040 |
Why?
|
| Time Factors | 1 | 2022 | 1491 | 0.040 |
Why?
|
| Proteomics | 1 | 2018 | 93 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 66 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 21 | 0.030 |
Why?
|
| Taxoids | 1 | 2016 | 10 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2016 | 23 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2015 | 4 | 0.030 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 3 | 0.030 |
Why?
|
| Hemoptysis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Esophagitis | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cough | 1 | 2015 | 9 | 0.030 |
Why?
|
| Chest Pain | 1 | 2015 | 19 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 17 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2015 | 32 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 42 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 177 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2015 | 94 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 117 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 68 | 0.030 |
Why?
|
| Diet | 1 | 2015 | 220 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 9 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 362 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 608 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 8 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 15 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 23 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 307 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 661 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 447 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 220 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 177 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 57 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 677 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2007 | 27 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 94 | 0.020 |
Why?
|